About Lupin Limited (LUPIN:NSE)
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, active pharmaceutical ingredients (APIs), and specialty products in India, the United States, Japan, and internationally. It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, anti-tuberculosis, and cephalosporin, as well as digital therapeutics platform for doctors and patients. The company is also involved in the provision of biosimilar and over-the-counter products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. It has a licensing, development, and commercialization agreement with Boehringer Ingelheim for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with cancers. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India. Read Less
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, active pharmaceutical ingredients (APIs), and specialty products in India, the United States, Japan, and internationally. It offers ...Read More
Company Website : https://www.lupin.com
Address : Kalpataru Inspire, Mumbai, India, 400055
Fiscal Year End : March
Currency:
INR
Country :
India